Welcome to our dedicated page for CS Diagnostics SEC filings (Ticker: CSDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The CS Diagnostics Corp. (CSDX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as it develops and commercializes advanced medical and protective technologies. CS Diagnostics Corp., a Wyoming-incorporated issuer trading on the OTCQB market, uses SEC filings to report material events, capital structure changes, and steps in its broader regulatory and growth strategy.
Among the key documents, investors can review Form 8-K filings such as the report describing the conversion of all outstanding Series B Preferred Stock held by affiliates CS Interpharm General Trading Co. LLC and CS Diagnostics Pharma GmbH into common shares. In that filing, the company explains how the conversion simplifies its equity capitalization, prepares for consolidated financial reporting, and aligns affiliate ownership with common shareholders. The filing also outlines the Securities Act exemptions relied upon and notes ongoing resale limitations under Rule 144 for affiliated holders.
CS Diagnostics Corp. has also discussed the submission of a registration statement draft for processing and future filing with the SEC, which it characterizes as an important step toward enhanced transparency, improved corporate governance, and expanded access to capital. As the company advances these efforts, investors can use this page to track new filings related to registration, periodic reporting, and additional material events.
Stock Titan’s platform pairs these filings with AI-powered summaries that highlight the main points of each document, helping readers understand how items such as preferred stock conversions, financing arrangements, and regulatory initiatives may affect CS Diagnostics Corp.’s structure and operations. Users can quickly scan filing types, dates, and topics, and then dive into full-text documents for deeper analysis of the company’s evolving disclosure record.
Thomas Graus filed a Schedule 13G reporting beneficial ownership of 13,392,434 shares of CS Diagnostics Corp. common stock, equal to 9.9% of the class as of the filing. The holding comprises 3,700,000 shares held directly and 9,692,434 shares issuable upon conversion of Series B preferred shares, although conversions are limited by a 9.9% cap in the Certificate of Designation. The filing states sole voting and dispositive power over the reported shares and excludes any securities held through entities where the filer lacks control. The filer certifies the stake was not acquired to change or influence control.
CS Diagnostics Corp. filed Amendment No. 1 to its Form 10 registration statement to register its common stock, par value $0.001 per share, under Section 12(g) of the Securities Exchange Act of 1934. The Wyoming corporation lists its principal executive offices in Neuss, Germany and classifies itself as a small reporting company.
The amendment primarily cross-references an information statement filed as Exhibit 99.1 for detailed disclosures on business, risk factors, financial information, ownership, governance, and executive compensation, and includes an amended financial period ending March 31, 2025 as an exhibit. The filing is signed on behalf of the company by Group CFO Mohammad EsSayed.